These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22306429)

  • 1. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa.
    Collnot EM; Ali H; Lehr CM
    J Control Release; 2012 Jul; 161(2):235-46. PubMed ID: 22306429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients.
    Schmidt C; Lautenschlaeger C; Collnot EM; Schumann M; Bojarski C; Schulzke JD; Lehr CM; Stallmach A
    J Control Release; 2013 Jan; 165(2):139-45. PubMed ID: 23127508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies.
    Coco R; Plapied L; Pourcelle V; Jérôme C; Brayden DJ; Schneider YJ; Préat V
    Int J Pharm; 2013 Jan; 440(1):3-12. PubMed ID: 22820482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
    Nakase H; Okazaki K; Tabata Y; Chiba T
    J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery nano/micro particles to inflamed intestinal mucosa in human.
    Park K
    J Control Release; 2013 Jan; 165(2):162. PubMed ID: 23265297
    [No Abstract]   [Full Text] [Related]  

  • 6. Polymeric nanoparticles for the selective therapy of inflammatory bowel disease.
    Wachsmann P; Lamprecht A
    Methods Enzymol; 2012; 508():377-97. PubMed ID: 22449936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease.
    Lamprecht A; Ubrich N; Yamamoto H; Schäfer U; Takeuchi H; Maincent P; Kawashima Y; Lehr CM
    J Pharmacol Exp Ther; 2001 Nov; 299(2):775-81. PubMed ID: 11602694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update.
    Dahan A; Amidon GL; Zimmermann EM
    Expert Rev Clin Immunol; 2010 Jul; 6(4):543-50. PubMed ID: 20594127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment.
    Veltkamp C; Anstaett M; Wahl K; Möller S; Gangl S; Bachmann O; Hardtke-Wolenski M; Länger F; Stremmel W; Manns MP; Schulze-Osthoff K; Bantel H
    Gut; 2011 Oct; 60(10):1345-53. PubMed ID: 21459928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
    Laroui H; Dalmasso G; Nguyen HT; Yan Y; Sitaraman SV; Merlin D
    Gastroenterology; 2010 Mar; 138(3):843-53.e1-2. PubMed ID: 19909746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic options to modulate barrier defects in inflammatory bowel disease.
    Hering NA; Schulzke JD
    Dig Dis; 2009; 27(4):450-4. PubMed ID: 19897959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical approaches to colon targeted drug delivery systems.
    Chourasia MK; Jain SK
    J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases.
    Youshia J; Lamprecht A
    Expert Opin Drug Deliv; 2016; 13(2):281-94. PubMed ID: 26637060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel cytokine-targeted therapies and intestinal inflammation.
    Waldner MJ; Neurath MF
    Curr Opin Pharmacol; 2009 Dec; 9(6):702-7. PubMed ID: 19674937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery strategies in the therapy of inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Fischer D; Stallmach A
    Adv Drug Deliv Rev; 2014 May; 71():58-76. PubMed ID: 24157534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of intestinal inflammation in the pathogenesis of spondylarthropathies].
    Mielants H; Veys EM
    Verh K Acad Geneeskd Belg; 1996; 58(2):93-116. PubMed ID: 8768479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel drug delivery strategies for the treatment of inflammatory bowel disease.
    Kesisoglou F; Zimmermann EM
    Expert Opin Drug Deliv; 2005 May; 2(3):451-63. PubMed ID: 16296767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled pulmonary drug and gene delivery using polymeric nano-carriers.
    Beck-Broichsitter M; Merkel OM; Kissel T
    J Control Release; 2012 Jul; 161(2):214-24. PubMed ID: 22192571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oral delivery systems for treatment of inflammatory bowel disease.
    Friend DR
    Adv Drug Deliv Rev; 2005 Jan; 57(2):247-65. PubMed ID: 15555741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.